MiNK Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MiNK Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.49M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.46M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($27.99M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($30.21M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($16.24M) | Mar 18, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.64M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.29M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.92M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($30.95M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($28.36M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($14.64M) | Mar 18, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.34M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $15.49M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $23.12M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $13.97M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $9.51M | Mar 18, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.93M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.56M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($15.76M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($18.87M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($12.83M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($8.34M) | Mar 18, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $73.6K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $250.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $249.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $95.2K | Mar 18, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.55M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $21.47M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $40.24M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.56M | Mar 18, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($19.59M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($18.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($401.3K) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $23.78M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($53.87M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | ($36.33M) | Mar 18, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($156.68M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($144.18M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($133.40M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($110.94M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($82.95M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($52.74M) | Mar 18, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.58M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.37M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $19.64M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $38.89M | Mar 24, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 24, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 24, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 3.96M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | 3.46M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 33.86M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 33.48M | Mar 24, 2023 |